Showing results (1-10 of 505) with videos related to
Sort By:
Pageof 51
Oncology (Williston Park, N.Y.)|October 21, 2011
Bladder cancer: imperatives for personalized medicineAshish M Kamat, Paul MathewExpert Review of Anticancer Therapy|December 23, 2003
Chemoprevention of superficial bladder cancerAshish M KamatUrologic Oncology|June 26, 2013
Commentary on "Predictive capacity of four comorbidity indices estimating perioperative mortality after radical cystectomy for urothelial carcinoma of the bladder." Mayr R, May M, Martini T, Lodde M, Pycha A, Comploj E, Wieland WF, Denzinger S, Otto W, Burger M, Fritsche HM. Department of Urology, Central Hospital of Bolzano, Bolzano, Italy: BJU Int 2012;110(6 Pt B):E222-7 [Epub 2012 Feb 7]Ashish M KamatUrologic Oncology|June 26, 2013
Commentary on "Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma." Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, Song W, Dabrow M, Brody M, Tuttle H, Hudes G, University of Pennsylvania, Philadelphia, PA: J Clin Oncol 2012;30(28):3545-51 [Epub 2012 Aug 27]Ashish M KamatUrologic Oncology|June 26, 2013
Commentary on "The clinical epidemiology of urachal carcinoma: results of a large, population based study." Bruins HM, Visser O, Ploeg M, Hulsbergen-van de Kaa CA, Kiemeney LA, Witjes JA, Department of Urology, Radboud University Medical Centre, Utrecht, The Netherlands: J Urol 2012;188(4):1102-7 [Epub 2012 Aug 15]Ashish M KamatCurrent Urology Reports|October 18, 2018
Current Use and Promise of Urinary Markers for Urothelial CancerWilliam Tabayoyong, Ashish M KamatExpert Review of Anticancer Therapy|December 21, 2004
Current state of immunotherapy for bladder cancerWassim Kassouf, Ashish M KamatThe Urologic Clinics of North America|November 24, 2019
Predictors of Response to Intravesical TherapyRoger Li, Ashish M KamatEuropean Urology|November 9, 2013
Myths and mysteries surrounding bacillus Calmette-Guérin therapy for bladder cancerAshish M Kamat, Sima PortenPageof 51